I'm upgrading Cytek Biosciences from "Hold" to "Buy" due to improving financials, expanding installed base, and strong demand for Aurora and Northern Lights systems. Cytek's Q3 FY2024 revenue up 7% YoY, driven by international demand; service revenue surged 25% YoY, boosting recurring revenue streams. The recently announced buyback plan went unnoticed, based on the EPS estimates revisions.
FREMONT, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
FREMONT, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock repurchase program for up to an additional aggregate of $50 million of its common stock, subject to compliance with applicable law, to succeed the expiration of the existing $50 million repurchase p...
FREMONT, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 36th Annual Healthcare Conference in New York, NY.
FREMONT, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that it has been named “Overall BioTech Company of the Year” in the fourth annual BioTech Breakthrough Awards program.
FREMONT, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) has introduced an Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system.
FREMONT, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) is set to elevate its presence at this year's premier clinical industry events across the globe.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.